case | 12 Oct 2021
Setterwalls has assisted CombiGene AB in its licensing agreement with Spark Therapeutics
![Responsive image](https://setterwalls.se/wp-content/uploads/2021/10/office_2-1-1200x500.jpg)
Setterwalls has, together with the Swiss law firm, Vischer, assisted CombiGene AB (listed on Stockholm Nasdaq First North Growth Market) in entering into an exclusive, global collaboration- and licensing agreement for CombiGene’s CG01 project.
The CG01 project is a gene therapy that aims to treat drug resistant focal epilepsy with Spark Therapeutics, a US-based company within the Roche Group.